Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Amino acid or derivative
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 10917
Molecular formula: C7H15NO3
IUPAC: (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate
Source: PC-L-CARNITINE
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Transports long-chain fatty-acid acyl groups toward mitochondrial metabolism; not a peptide.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context
Replacement in defined deficiencies/products and community “fat burner” marketing. Normal physiology does not show that injecting it causes fat loss.
Human evidence
Studies depend on deficiency, disease, route and outcome. Institutional review does not support turning presence in Lipo-C into clinical efficacy of the whole blend.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
Studies depend on deficiency, disease, route and outcome. Institutional review does not support turning presence in Lipo-C into clinical efficacy of the whole blend.
Studies depend on deficiency, disease, route and outcome. Institutional review does not support turning presence in Lipo-C into clinical efficacy of the whole blend.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: the cited IV levocarnitine has indications for inborn errors with secondary deficiency and dialysis-associated deficiency. This is not fat-loss/Lipo-C authorization.
Adverse effects and unknowns
High oral amounts can cause gastrointestinal symptoms/body odor; the oral profile does not establish injectable-product or combination safety.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
L-carnitine · 312 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07783399 · The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF ProcessRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07862725 · Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled TrialRegistry status: Not yet recruitingLast update posted: October 7, 2026Query verification: October 16, 2026
NCT06126315 · Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALSRegistry status: RecruitingLast update posted: October 6, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- ODS-CARNITINE
October 16, 2026
- PC-L-CARNITINE
PubChem L-carnitine (CID 10917)
October 16, 2026
- REG-CARNITINE
DailyMed: Levocarnitine injection
October 16, 2026
- SEARCH-PUBMED-l-carnitine
PubMed/MED targeted search: TITLE:"L-carnitine" AND TITLE:randomized
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026